Colombia vs Mongolia: Average cost of multi drug-resistant tuberculosis treatment
Colombia
1,528 constant 2022 US$
in 2024
Mongolia
1,500 constant 2022 US$
in 2024
Colombia rank
32nd
Mongolia rank
34th
Average cost of multi drug-resistant tuberculosis treatment over time
- Colombia
- Mongolia
How they compare
Colombia currently reports 1,528 constant 2022 US$ against 1,500 constant 2022 US$ in Mongolia, a difference of 28 constant 2022 US$.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Mongolia ahead.
Colombia ranks 32nd and Mongolia ranks 34th of 92 countries.
Mongolia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Colombia | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,500 constant 2022 US$ | 2,573 constant 2022 US$ | 73.33 constant 2022 US$ | Mongolia |
| 2020s | 953 constant 2022 US$ | 1,455 constant 2022 US$ | 501.6 constant 2022 US$ | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Colombia or Mongolia?
- Colombia, at 1,528 constant 2022 US$ against 1,500 constant 2022 US$ in Mongolia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Colombia and Mongolia?
- 28 constant 2022 US$, with Colombia ahead.
- How many years of comparable data are there for Colombia and Mongolia?
- 8 years are reported by both, from 2017 to 2024.
- How do Colombia and Mongolia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Colombia ranks 32nd and Mongolia ranks 34th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.